Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines
Spyros Chalkias(Moderna Therapeutics (United States)), Rituparna Das(Moderna Therapeutics (United States)), Adam Brosz(Meridian Clinical Research), Bethany Girard(Moderna Therapeutics (United States)), Nichole McGhee(Moderna Therapeutics (United States)), Joanne E. Tomassini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jing Feng(Moderna Therapeutics (United States)), Arshan Nasir(Moderna Therapeutics (United States)), Jacqueline M. Miller(Moderna Therapeutics (United States)), Darin K. Edwards(Moderna Therapeutics (United States)), Kaichun Wu(Xijing Hospital), Laura E. Avena(Moderna Therapeutics (United States)), Lindsey R. Baden(Brigham and Women's Hospital), Diana Lee, Weiping Deng(Yunnan Agricultural University), Brandon Essink(Velocity Clinical Research (United States)), David C. Montefiori(Duke University)
Cited by 63
Related Papers
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k